Amotiv Limited (AOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amotiv Limited (AOV) has a cash flow conversion efficiency ratio of 0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$68.96 Million ≈ $49.88 Million USD) by net assets (CA$767.27 Million ≈ $555.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amotiv Limited net asset quality index to measure how much of total assets are equity-financed.
Amotiv Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amotiv Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Amotiv Limited to evaluate the quality of earnings relative to operating cash generation.
Amotiv Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amotiv Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lanzhou Foci Pharmaceutical Co Ltd
SHE:002644
|
0.041x |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
-0.017x |
|
Korea Investment Holdings Co Ltd
KO:071055
|
-0.185x |
|
Tianjin Keyvia Electric Co Ltd
SHE:300407
|
0.053x |
|
Chengdu Xiling Power Science & Technology Incorporated Co Class A
SHE:300733
|
0.070x |
|
Guangdong Super Telecom
SHG:603322
|
0.053x |
|
Shanghai New World Co Ltd
SHG:600628
|
0.020x |
|
Jenkem Technology Co Ltd
SHG:688356
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Amotiv Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amotiv Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Amotiv Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$767.27 Million ≈ $555.03 Million |
CA$68.96 Million ≈ $49.88 Million |
0.090x | +96.96% |
| 2024-12-31 | CA$795.11 Million ≈ $575.17 Million |
CA$36.28 Million ≈ $26.24 Million |
0.046x | -5.18% |
| 2023-12-31 | CA$746.87 Million ≈ $540.28 Million |
CA$35.94 Million ≈ $26.00 Million |
0.048x | -1.83% |
| 2022-12-31 | CA$825.86 Million ≈ $597.41 Million |
CA$40.48 Million ≈ $29.28 Million |
0.049x | -7.50% |
| 2021-12-31 | CA$842.02 Million ≈ $609.10 Million |
CA$44.62 Million ≈ $32.28 Million |
0.053x | +484.77% |
| 2020-12-31 | CA$886.24 Million ≈ $641.09 Million |
CA$-12.21 Million ≈ $-8.83 Million |
-0.014x | -374.21% |
| 2019-12-31 | CA$915.11 Million ≈ $661.97 Million |
CA$4.60 Million ≈ $3.32 Million |
0.005x | +190.14% |
| 2018-12-31 | CA$1.03 Billion ≈ $745.11 Million |
CA$-5.74 Million ≈ $-4.15 Million |
-0.006x | -123.54% |
| 2017-12-31 | CA$991.21 Million ≈ $717.02 Million |
CA$23.46 Million ≈ $16.97 Million |
0.024x | +57.32% |
| 2016-12-31 | CA$979.72 Million ≈ $708.71 Million |
CA$14.74 Million ≈ $10.66 Million |
0.015x | +26.49% |
| 2015-12-31 | CA$642.06 Million ≈ $464.46 Million |
CA$7.64 Million ≈ $5.52 Million |
0.012x | +609.11% |
| 2014-12-31 | CA$478.99 Million ≈ $346.49 Million |
CA$803.34K ≈ $581.13K |
0.002x | -- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more